Clinical trials
HR+ Breast Cancer clinical trials
Below are recruiting hr+ breast cancer clinical trials, each written for real people, not researchers. We’re tracking 335 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06831838Recruiting
Pain management program for breast cancer survivors with joint pain
This trial tests a cognitive behavioral therapy (CBT) based program to help relieve joint and muscle pain caused by aromatase inhibitors, a common hormone therapy for breast cancer. It aims to improve your quality of life and reduce symptoms.
Jacksonville, FloridaAges 18 years+ - NCT06545942RecruitingPhase 1
Studying MOMA-313 for advanced or metastatic solid tumors
This trial tests a new oral drug, MOMA-313, alone or with another drug (olaparib), in people whose cancer has a specific DNA repair problem (HR-deficient mutation). It aims to see if the drug can shrink tumors or slow their growth.
Goodyear, ArizonaAges 18 years+ - NCT06433609RecruitingPhase 2
ADC plus immunotherapy for advanced HER2-negative breast cancer
This trial tests a combination of an antibody-drug conjugate (ADC) and an immunotherapy drug (adebrelimab) for people with advanced HER2-negative breast cancer that has stopped responding to prior treatments. The goal is to see if this combination can help shrink or slow the cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT06401421Recruiting
Blood test for tumor DNA after breast cancer chemo
This study tests a new blood test to see if it can find tiny bits of tumor DNA after chemotherapy. If you have a larger or higher-risk breast cancer and are getting chemotherapy before surgery, you may join. The test could help doctors know if your cancer is gone or if more treatment is needed.
Anchorage, AlaskaAges 18 years+ - NCT06380751RecruitingPhase 3
New targeted therapy for BRCA/PALB2-mutated HR+ breast cancer
This trial tests a new combination of targeted therapies (saruparib plus camizestrant or hormone therapy) against standard treatments for people with a specific type of advanced breast cancer. It may be a good option if you have a BRCA1, BRCA2, or PALB2 gene mutation and have not yet had treatment for your advanced disease.
Gilbert, ArizonaAges 18 years+ - NCT06274515RecruitingPhase 4
Study of resistance to breast cancer therapies
This study looks at why some breast cancers stop responding to treatment. It involves taking a small sample of your tumor (biopsy) and blood to understand resistance. If you have HER2-positive or triple-negative breast cancer that is growing despite treatment, you may be able to join.
AnderlechtAges 18 years+ - NCT06105684RecruitingPhase 2
Low-dose capecitabine for advanced breast cancer
This trial tests a lower dose of the chemotherapy drug capecitabine in people with advanced breast cancer that is HER2 negative. It aims to see if this gentler dose works well, especially for older or frailer patients who may have more difficulty with standard treatment.
Birmingham, AlabamaAges 60 years+ - NCT05876065Recruiting
Maintenance chemotherapy to help control advanced breast cancer
This trial studies whether taking a combination of capecitabine and cyclophosphamide after your best prior treatment can help keep advanced breast cancer from growing. It may help people whose disease has already responded or is stable after “salvage” treatment.
ShanghaiAges 18 years+ - NCT05528133RecruitingPhase 2
Personalized radiation based on tumor genetics in triple-negative breast cancer
This trial tests whether using tumor “genetics” (information from your biopsy) to guide radiation planning can improve treatment for triple-negative breast cancer. It may help by aiming radiation more precisely while still using standard approaches where needed.
Clearwater, FloridaAges 18 years+ - NCT04680715RecruitingPhase 2
Tested radiation before and after breast surgery in older women
This Phase 2 trial looks at a specific radiation timing and technique around the time of breast-conserving surgery. It may help reduce the chance the cancer comes back in selected older patients with certain early-stage, hormone-positive, HER2-negative breast cancers.
Clermont-FerrandAges 65 years+ - NCT07350928RecruitingPhase 3
Nasal spray before breast-saving surgery for calm wakefulness
This trial tests a nasal spray (dexmedetomidine) given before breast-conserving surgery to help you stay calm and comfortable while awake during the procedure. It aims to improve your recovery and waking experience after surgery.
TianjinAges 20–70 - NCT07072728RecruitingPhase 2
Psilocybin therapy for anxiety in cancer patients
This trial tests whether psilocybin (a psychedelic drug given with talk therapy) can help people with cancer who have adjustment disorder—a condition where a cancer diagnosis causes severe anxiety or stress. It focuses on reducing anxiety and improving emotional well-being.
Abbotsford, VictoriaAges 18–80 - NCT07801508RecruitingPhase 1
Trial of a new imaging agent for people with advanced solid tumors
This trial tests a radioactive imaging agent that may help doctors see tumors more clearly using a special scan. It is designed for adults with certain breast, lung, or stomach cancers that have spread.
Darlinghurst, New South WalesAges 18 years+ - NCT07145255RecruitingPhase 1/Phase 2
Study of MBRC-201 for advanced solid tumors
This trial tests a new drug, MBRC-201, for people with advanced solid tumors that have not responded to standard treatments. The goal is to find the best dose and see if it helps shrink tumors or slow their growth.
San Francisco, CaliforniaAges 18 years+ - NCT06833853Recruiting
Blood test study for women with advanced breast cancer
This study looks at a blood test that measures certain markers on cancer cells (CTCs) and genetic material in the blood (cfDNA/RNA) in women with metastatic breast cancer. It aims to better understand the cancer and guide treatment decisions.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05906407Recruiting
Genetic-guided treatment planning for high-risk early breast cancer
This study uses tumor genetic testing to help plan more precise treatment for people with early high-risk breast cancer. You may be asked to give a recent tumor sample so researchers can match your cancer features with the best available options.
AugsburgAges 18–80 - NCT05866458Recruiting
Radiation after lumpectomy for node-negative breast cancer
This trial studies whether a specific radiation approach after lumpectomy can be helpful for certain people with early breast cancer that did not spread to lymph nodes at diagnosis. It focuses on people who finish neoadjuvant (before-surgery) treatment and reach a full response on final pathology.
Cudgen, CudgenAges 50 years+ - NCT03417115Recruiting
Breast cancer registry study of treatment and outcomes
This is a registry study that collects real-world information about breast cancer care at the start of treatment. It may help researchers better understand which treatments work best for different groups of people.
Many LocationsAges 18 years+ - NCT06993506Recruiting
SKB264 alone or combined for advanced HER2- breast cancer
This study is a real-world treatment trial for people with advanced HER2-negative breast cancer (either triple-negative or HR+/HER2-). It tests a drug called SKB264, given alone or with other therapies, and aims to see how well it works in everyday clinical practice.
Hefei, AnhuiAges 18 years+ - NCT05000294RecruitingPhase 1/Phase 2
Atezolizumab plus tivozanib for hard-to-treat “cold” cancers
This early-stage study tests whether combining atezolizumab and tivozanib can shrink advanced, hard-to-treat cancers that do not strongly activate the immune system (“immunologically cold”). It is for people whose cancer has already been treated or has no good standard options.
Gainesville, FloridaAges 18–99 - NCT06666270RecruitingPhase 1
SYN818 for advanced solid tumors with DNA repair defects
This trial tests a new drug called SYN818 for people with advanced breast, ovarian, prostate, or other solid tumors that have stopped responding to standard treatments. It is designed for patients whose tumors have a specific DNA repair problem (BRCA mutation or other HR pathway deficiency).
Zhengzhou, HenanAges 18 years+ - NCT05911958RecruitingPhase 2
Study drug before surgery for HER2-low, HR-positive breast cancer
This trial tests SHR-A1811 given before surgery (neoadjuvant treatment) for breast cancer that is hormone-receptor positive (HR-positive) and HER2-low. It aims to shrink or control the cancer early and see how well this approach works compared with standard care.
Zhengzhou, HenanAges 18–70 - NCT07666555RecruitingPhase 2
Culmerciclib rechallenge for HR+ HER2- breast cancer
This trial tests a new drug called Culmerciclib for women with advanced HR-positive, HER2-negative breast cancer that has stopped responding to a CDK4/6 inhibitor with hormone therapy. The goal is to see if giving this drug again can help when other treatments no longer work.
ShanghaiAges 18–75 - NCT07776951Recruiting
Physical activity for breast cancer patients during treatment
This study tests whether a supervised physical activity program can help breast cancer patients reduce inflammation and improve health during neoadjuvant treatment (chemotherapy or immunotherapy given before surgery). The goal is to see if exercise can improve treatment outcomes and overall well-being.
MilanAges 18 years+
Hear when a new HR+ Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hr+ breast cancer?
- Yes. Clin2 currently lists 335 recruiting hr+ breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hr+ breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hr+ breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.